Tamsulosin in urology: beyond benign prostatic hyperplasia
- 39 Downloads
Tamsulosin, a third-generation uroselective α1A adrenergic receptor blocker (antagonist), has been approved for the treatment of signs and symptoms of benign prostatic hyperplasia for more than two decades. Apart from this approved use, more recent evidence has been published regarding the off-label use of tamsulosin in various other urological conditions. However, further research is needed regarding the use of tamsulosin in these indications. This review highlights the possible therapeutic uses of tamsulosin for the management of various urological conditions.
Compliance with ethical standards
Conflict of interest
Hiren Prajapati, Alok Chaturvedi, Nilanj Dave and Amit B. Jain are salaried employees of Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat, India.
- 3.Flomax® label. Package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020579s029lbl.pdf Accessed 11 Nov 2018.
- 4.Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 2012;367:248–57Google Scholar
- 6.Lewis W. Off-label use tamsulosin in the presence of uncomplicated radiographically proven distal urolithiasis [thesis]. Paper no. 162. Hillsboro: School of Physician Assistant Studies; 2009. p. 8–34.Google Scholar
- 12.Altarac S. Alpha-adrenergic blockers as a support in the treatment of acute urinary retention [in Croatian]. Lijec Vjesn. 2006;128(7–8):233–7.Google Scholar
- 17.Liucheng D, Zhongqing W. Tamsulosin application for the treatment of advanced prostate cancer accompany with bladder outlet obstruction [abstract no. 642]. https://www.ics.org/Abstracts/Publish/134/000642.pdf. Accessed 27 Nov 2018.
- 18.Tubaro A, De Nunzio C, Mariani S, et al. Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate-specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy. Urology. 2010;76(2):436–41.CrossRefGoogle Scholar
- 20.Djavan B, Shariat S, Fakhari M, et al. Neoadjuvant and adjuvant α-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial. Urology. 1999;53(2):251–9.CrossRefGoogle Scholar
- 21.Abrams P, Amarenco G, Bakke A, et al. European Tamsulosin Neurogenic Lower Urinary Tract Dysfunction Study Group. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003;170(4 Pt 1):1242–51.Google Scholar
- 23.Moussa AS, Ibrahim RM, Abdelbary AM, et al. Tamsulosin to relieve JJ stent related discomfort: a prospective randomized placebo controlled crossover study. J Urol Res. 2017;4(4):1092.Google Scholar
- 24.Navanimitkul N, Lojanapiwat B. Efficacy of tamsulosin 0.4 mg/day in relieving double-J stent-related symptoms: a randomized controlled study. J Int Med Res. 2010;38(4):1436–41.Google Scholar
- 25.Aggarwal SP, Priyadarshi S, Tomar V, et al. A randomized controlled trial to compare the safety and efficacy of tadalafil and tamsulosin in relieving double J stent related symptoms. Adv Urol. 2015;592175. https://doi.org/10.1155/2015/592175.
- 30.Bhat G, Bhat A. BKP 02: prospective double blind randomised study to evaluate the efficacy of siliodosin 8 mg as on demand, reversible, male oral contraceptive. Indian J Urol. 2018;34(Suppl 1):S7–72.Google Scholar